BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 23628040)

  • 21. Mutations of the 5' noncoding region of the BCL-6 gene in primary bone lymphomas.
    Gianelli U; Ponzoni M; Moro A; Alfano RM; Pellegrini C; Giardini R; Patriarca C; Armiraglio E; Bosari S; Parafioriti A; Coggi G
    Ann Hematol; 2003 Nov; 82(11):691-5. PubMed ID: 14513282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Influence of transplantation and some clinical factors on prognosis of patients with diffuse large B-cell lymphoma].
    Zhao SX; Han Y; Zhu Q; Wang Q; Zhang WJ; Chen XC; Sun AN; Jin ZM; Qiu HY; Tang XW; Fu ZZ; He GS; Miao M; Ma X; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):623-7. PubMed ID: 23815910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma.
    Yu B; Zhou X; Li B; Xiao X; Yan S; Shi D
    Ann Hematol; 2011 Jun; 90(6):701-8. PubMed ID: 21120478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population.
    Kim IS; Kim DC; Kim HG; Eom HS; Kong SY; Shin HJ; Hwang SH; Lee EY; Kim S; Lee GW
    Cancer Genet Cytogenet; 2010 Jan; 196(1):31-7. PubMed ID: 19963133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinicopathologic significance of bcl-6 gene rearrangement and expression in three molecular subgroups of diffuse large B-cell lymphoma].
    Xu FP; Liu YH; Luo XL; Zhuang HG; Li L; Luo DL; Xu J; Zhang F; Zhang MH; Du X; Li WY
    Zhonghua Bing Li Xue Za Zhi; 2008 Jun; 37(6):371-6. PubMed ID: 19031715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCL3 rearrangement, amplification and expression in diffuse large B-cell lymphoma.
    Ibrahim HA; Amen F; Reid AG; Naresh KN
    Eur J Haematol; 2011 Dec; 87(6):480-5. PubMed ID: 21752100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study.
    Munch-Petersen HD; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Sniegowski MC; Vemuganti GK; Heegaard S
    JAMA Ophthalmol; 2015 Feb; 133(2):165-73. PubMed ID: 25393033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
    Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.
    Chatzitolios A; Venizelos I; Tripsiannis G; Anastassopoulos G; Papadopoulos N
    Ann Hematol; 2010 Sep; 89(9):889-96. PubMed ID: 20352431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.
    Marques SC; Ranjbar B; Laursen MB; Falgreen S; Bilgrau AE; Bødker JS; Jørgensen LK; Primo MN; Schmitz A; Ettrup MS; Johnsen HE; Bøgsted M; Mikkelsen JG; Dybkær K
    Exp Hematol; 2016 Apr; 44(4):238-46.e2. PubMed ID: 26854484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma.
    Sebastián E; Alcoceba M; Martín-García D; Blanco Ó; Sanchez-Barba M; Balanzategui A; Marín L; Montes-Moreno S; González-Barca E; Pardal E; Jiménez C; García-Álvarez M; Clot G; Carracedo Á; Gutiérrez NC; Sarasquete ME; Chillón C; Corral R; Prieto-Conde MI; Caballero MD; Salaverria I; García-Sanz R; González M
    Ann Hematol; 2016 Jan; 95(2):253-62. PubMed ID: 26573278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BCL-2 overexpression overcomes cell of origin stratification in diffuse large B-cell lymphoma.
    Damlaj M; Yassin R; Al-Shieban S; Pasha T; Alzahrani M; Alhejazi A; Alaskar A
    Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):174-177. PubMed ID: 30075095
    [No Abstract]   [Full Text] [Related]  

  • 33. Using the Precision Lasso for gene selection in diffuse large B cell lymphoma cancer.
    Pourhamidi R; Moslemi A
    J Egypt Natl Canc Inst; 2023 Jun; 35(1):19. PubMed ID: 37357234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diffuse large B-cell lymphoma genetics - simplifying the subtyping.
    Hodson DJ
    Br J Haematol; 2021 Dec; 195(5):651-652. PubMed ID: 34492737
    [No Abstract]   [Full Text] [Related]  

  • 35. Methyl methanesulfonate induces necroptosis in human lung adenoma A549 cells through the PIG-3-reactive oxygen species pathway.
    Jiang Y; Shan S; Chi L; Zhang G; Gao X; Li H; Zhu X; Yang J
    Tumour Biol; 2016 Mar; 37(3):3785-95. PubMed ID: 26472723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Expression and significance of p53-inducible gene 3 (PIG-3) in diffuse large B cell lymphoma].
    Zhu F; Zhang LQ; Gu WJ; Zhu W; Guo YL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):396-8. PubMed ID: 23628040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prognostic value of P53 aberrations in diffuse large B-cell lymphoma].
    Lu JT; Cen L; Zhou M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):100-2. PubMed ID: 22391175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and validation of a two-gene expression index for subtype classification and prognosis in Diffuse Large B-Cell Lymphoma.
    Xu Q; Tan C; Ni S; Wang Q; Wu F; Liu F; Ye X; Meng X; Sheng W; Du X
    Sci Rep; 2015 May; 5():10006. PubMed ID: 25940947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
    Obermann EC; Csato M; Dirnhofer S; Tzankov A
    J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.